Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype

Ulrike Zinnall, Veronika Weyerer, Eva Compérat, Philippe Camparo, Nadine T. Gaisa, Ruth Knuechel-Clarke, Aurel Perren, Alessandro Lugli, Marieta Toma, Gustavo Baretton, Glen Kristiansen, Ralph M. Wirtz, Liang Cheng, Bernd Wullich, Robert Stoehr, Arndt Hartmann, Simone Bertz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Comprehensive molecular analyses of urothelial bladder cancer (UBC) have defined distinct subtypes with potential therapeutic implications. In this study, we focused on micropapillary urothelial carcinoma (MPUC), an aggressive, histomorphologically defined rare variant. Apart from genetic alterations shared with conventional UBC, alterations of the HER2 gene have been reported in higher frequencies. However, only small cohorts of MPUCs have been analyzed, and the real impact is still unclear. We collected a cohort of 94 MPUCs and immunohistochemically tested HER2, basal (CD44, CK5, EGFR, p63) and luminal (CD24, FOXA1, GATA3, CK20) markers to allocate MPUC to a molecular subtype. Additionally, HER2 amplification status was assigned by chromogenic in situ hybridization. Sanger sequencing of exon 4 and 8 was used to test for HER2 mutations. Kruskal-Wallis test was calculated to compare marker distribution between proportions of the MPUC component. HER2 2+/3+ staining scores were identified in 39.6% of 91 analyzed MPUCs and were not differentially distributed among the proportion of the MPUC component (P =.89). Additionally, CISH analysis revealed 30% of HER2-amplified tumors independently of the MPUC fraction. In 6/90 evaluable MPUCs, a p.S310F HER2 mutation was detected. Overexpression of luminal markers was observed in the majority of MPUC. Our investigations of the largest cohort of analyzed MPUC demonstrate that HER2 overexpression and amplifications are common genetic alterations and identification of overexpressed luminal markers allows subclassification to the luminal subtype. These findings highlight the need of histomorphological recognition of MPUC and analysis of HER2 status and the luminal molecular subtype for potential targeted therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)55-64
Number of pages10
JournalHuman Pathology
Volume80
DOIs
StatePublished - Oct 1 2018

Fingerprint

Carcinoma
Urinary Bladder Neoplasms
erbB-2 Genes
Mutation
In Situ Hybridization
Exons
Staining and Labeling
Therapeutics
Neoplasms

Keywords

  • HER2
  • Micropapillary variant
  • Molecular subtype
  • Targeted therapy
  • Urothelial bladder cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Zinnall, U., Weyerer, V., Compérat, E., Camparo, P., Gaisa, N. T., Knuechel-Clarke, R., ... Bertz, S. (2018). Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Human Pathology, 80, 55-64. https://doi.org/10.1016/j.humpath.2018.05.022

Micropapillary urothelial carcinoma : evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. / Zinnall, Ulrike; Weyerer, Veronika; Compérat, Eva; Camparo, Philippe; Gaisa, Nadine T.; Knuechel-Clarke, Ruth; Perren, Aurel; Lugli, Alessandro; Toma, Marieta; Baretton, Gustavo; Kristiansen, Glen; Wirtz, Ralph M.; Cheng, Liang; Wullich, Bernd; Stoehr, Robert; Hartmann, Arndt; Bertz, Simone.

In: Human Pathology, Vol. 80, 01.10.2018, p. 55-64.

Research output: Contribution to journalArticle

Zinnall, U, Weyerer, V, Compérat, E, Camparo, P, Gaisa, NT, Knuechel-Clarke, R, Perren, A, Lugli, A, Toma, M, Baretton, G, Kristiansen, G, Wirtz, RM, Cheng, L, Wullich, B, Stoehr, R, Hartmann, A & Bertz, S 2018, 'Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype', Human Pathology, vol. 80, pp. 55-64. https://doi.org/10.1016/j.humpath.2018.05.022
Zinnall, Ulrike ; Weyerer, Veronika ; Compérat, Eva ; Camparo, Philippe ; Gaisa, Nadine T. ; Knuechel-Clarke, Ruth ; Perren, Aurel ; Lugli, Alessandro ; Toma, Marieta ; Baretton, Gustavo ; Kristiansen, Glen ; Wirtz, Ralph M. ; Cheng, Liang ; Wullich, Bernd ; Stoehr, Robert ; Hartmann, Arndt ; Bertz, Simone. / Micropapillary urothelial carcinoma : evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. In: Human Pathology. 2018 ; Vol. 80. pp. 55-64.
@article{1b96ca2726c046c9a875c26df573d3b0,
title = "Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype",
abstract = "Comprehensive molecular analyses of urothelial bladder cancer (UBC) have defined distinct subtypes with potential therapeutic implications. In this study, we focused on micropapillary urothelial carcinoma (MPUC), an aggressive, histomorphologically defined rare variant. Apart from genetic alterations shared with conventional UBC, alterations of the HER2 gene have been reported in higher frequencies. However, only small cohorts of MPUCs have been analyzed, and the real impact is still unclear. We collected a cohort of 94 MPUCs and immunohistochemically tested HER2, basal (CD44, CK5, EGFR, p63) and luminal (CD24, FOXA1, GATA3, CK20) markers to allocate MPUC to a molecular subtype. Additionally, HER2 amplification status was assigned by chromogenic in situ hybridization. Sanger sequencing of exon 4 and 8 was used to test for HER2 mutations. Kruskal-Wallis test was calculated to compare marker distribution between proportions of the MPUC component. HER2 2+/3+ staining scores were identified in 39.6{\%} of 91 analyzed MPUCs and were not differentially distributed among the proportion of the MPUC component (P =.89). Additionally, CISH analysis revealed 30{\%} of HER2-amplified tumors independently of the MPUC fraction. In 6/90 evaluable MPUCs, a p.S310F HER2 mutation was detected. Overexpression of luminal markers was observed in the majority of MPUC. Our investigations of the largest cohort of analyzed MPUC demonstrate that HER2 overexpression and amplifications are common genetic alterations and identification of overexpressed luminal markers allows subclassification to the luminal subtype. These findings highlight the need of histomorphological recognition of MPUC and analysis of HER2 status and the luminal molecular subtype for potential targeted therapeutic strategies.",
keywords = "HER2, Micropapillary variant, Molecular subtype, Targeted therapy, Urothelial bladder cancer",
author = "Ulrike Zinnall and Veronika Weyerer and Eva Comp{\'e}rat and Philippe Camparo and Gaisa, {Nadine T.} and Ruth Knuechel-Clarke and Aurel Perren and Alessandro Lugli and Marieta Toma and Gustavo Baretton and Glen Kristiansen and Wirtz, {Ralph M.} and Liang Cheng and Bernd Wullich and Robert Stoehr and Arndt Hartmann and Simone Bertz",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.humpath.2018.05.022",
language = "English (US)",
volume = "80",
pages = "55--64",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Micropapillary urothelial carcinoma

T2 - evaluation of HER2 status and immunohistochemical characterization of the molecular subtype

AU - Zinnall, Ulrike

AU - Weyerer, Veronika

AU - Compérat, Eva

AU - Camparo, Philippe

AU - Gaisa, Nadine T.

AU - Knuechel-Clarke, Ruth

AU - Perren, Aurel

AU - Lugli, Alessandro

AU - Toma, Marieta

AU - Baretton, Gustavo

AU - Kristiansen, Glen

AU - Wirtz, Ralph M.

AU - Cheng, Liang

AU - Wullich, Bernd

AU - Stoehr, Robert

AU - Hartmann, Arndt

AU - Bertz, Simone

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Comprehensive molecular analyses of urothelial bladder cancer (UBC) have defined distinct subtypes with potential therapeutic implications. In this study, we focused on micropapillary urothelial carcinoma (MPUC), an aggressive, histomorphologically defined rare variant. Apart from genetic alterations shared with conventional UBC, alterations of the HER2 gene have been reported in higher frequencies. However, only small cohorts of MPUCs have been analyzed, and the real impact is still unclear. We collected a cohort of 94 MPUCs and immunohistochemically tested HER2, basal (CD44, CK5, EGFR, p63) and luminal (CD24, FOXA1, GATA3, CK20) markers to allocate MPUC to a molecular subtype. Additionally, HER2 amplification status was assigned by chromogenic in situ hybridization. Sanger sequencing of exon 4 and 8 was used to test for HER2 mutations. Kruskal-Wallis test was calculated to compare marker distribution between proportions of the MPUC component. HER2 2+/3+ staining scores were identified in 39.6% of 91 analyzed MPUCs and were not differentially distributed among the proportion of the MPUC component (P =.89). Additionally, CISH analysis revealed 30% of HER2-amplified tumors independently of the MPUC fraction. In 6/90 evaluable MPUCs, a p.S310F HER2 mutation was detected. Overexpression of luminal markers was observed in the majority of MPUC. Our investigations of the largest cohort of analyzed MPUC demonstrate that HER2 overexpression and amplifications are common genetic alterations and identification of overexpressed luminal markers allows subclassification to the luminal subtype. These findings highlight the need of histomorphological recognition of MPUC and analysis of HER2 status and the luminal molecular subtype for potential targeted therapeutic strategies.

AB - Comprehensive molecular analyses of urothelial bladder cancer (UBC) have defined distinct subtypes with potential therapeutic implications. In this study, we focused on micropapillary urothelial carcinoma (MPUC), an aggressive, histomorphologically defined rare variant. Apart from genetic alterations shared with conventional UBC, alterations of the HER2 gene have been reported in higher frequencies. However, only small cohorts of MPUCs have been analyzed, and the real impact is still unclear. We collected a cohort of 94 MPUCs and immunohistochemically tested HER2, basal (CD44, CK5, EGFR, p63) and luminal (CD24, FOXA1, GATA3, CK20) markers to allocate MPUC to a molecular subtype. Additionally, HER2 amplification status was assigned by chromogenic in situ hybridization. Sanger sequencing of exon 4 and 8 was used to test for HER2 mutations. Kruskal-Wallis test was calculated to compare marker distribution between proportions of the MPUC component. HER2 2+/3+ staining scores were identified in 39.6% of 91 analyzed MPUCs and were not differentially distributed among the proportion of the MPUC component (P =.89). Additionally, CISH analysis revealed 30% of HER2-amplified tumors independently of the MPUC fraction. In 6/90 evaluable MPUCs, a p.S310F HER2 mutation was detected. Overexpression of luminal markers was observed in the majority of MPUC. Our investigations of the largest cohort of analyzed MPUC demonstrate that HER2 overexpression and amplifications are common genetic alterations and identification of overexpressed luminal markers allows subclassification to the luminal subtype. These findings highlight the need of histomorphological recognition of MPUC and analysis of HER2 status and the luminal molecular subtype for potential targeted therapeutic strategies.

KW - HER2

KW - Micropapillary variant

KW - Molecular subtype

KW - Targeted therapy

KW - Urothelial bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=85052433499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052433499&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2018.05.022

DO - 10.1016/j.humpath.2018.05.022

M3 - Article

C2 - 29885409

AN - SCOPUS:85052433499

VL - 80

SP - 55

EP - 64

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -